Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how the neighbourhood health framework will support the early identification and prevention of chronic kidney disease.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Neighbourhood Health Framework is designed to provide clarity and consistency to integrated care boards (ICBs), local authorities, and their partners, in developing and scaling neighbourhood health.
It is important that reforms are locally led, as ICBs and local authorities are best placed to design services that make sense for their local populations. Local systems can choose to go further than the minimum aims set out in the framework, and this could include a focus on chronic kidney disease.
Early diagnosis of chronic kidney disease is supported through widespread access to blood and urine tests across the National Health Service, including in primary care and community diagnostic services.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, in the light of the report by the Health Services Safety Investigations Body Insulin: supporting safe self-administration for patients in the community with a mental health problem, published on 26 February, what steps they plan to take to ensure that vulnerable patients are appropriately supported to administer insulin safely after discharge from hospital.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England is considering the Health Services Safety Investigations Body’s report and will respond to the recommendation in the report in due course.
To reduce insulin related harm, the NHS Getting It Right First Time (GIRFT) programme published guidance in April 2025 to support trusts to establish Diabetes Safety Boards. GIRFT is also undertaking a pilot across 20 integrated care systems as part of a Community and District Nurse Insulin Programme, which works to empower community diabetes nurses and district nursing teams to support patients at home requiring insulin administration.
To further support services to provide high quality personalised care for all patients needing secondary mental health services, including those with diabetes, NHS England has shared new draft guidance with systems, the Mental Health Personalised Care Framework, sets out how services must effectively assess, plan, and manage people's care in collaboration with all relevant teams, including how they assess safety and risks of harm.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, in the light of the report by the Health Services Safety Investigations Body Insulin: supporting safe self-administration for patients in the community with a mental health problem, published on 26 February, what assessment they have made of the risks to patient safety of inadequate assessment of a patient's ability to self-administer insulin prior to discharge from hospital
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England is considering the Health Services Safety Investigations Body’s report and will respond to the recommendation in the report in due course.
To reduce insulin related harm, the NHS Getting It Right First Time (GIRFT) programme published guidance in April 2025 to support trusts to establish Diabetes Safety Boards. GIRFT is also undertaking a pilot across 20 integrated care systems as part of a Community and District Nurse Insulin Programme, which works to empower community diabetes nurses and district nursing teams to support patients at home requiring insulin administration.
To further support services to provide high quality personalised care for all patients needing secondary mental health services, including those with diabetes, NHS England has shared new draft guidance with systems, the Mental Health Personalised Care Framework, sets out how services must effectively assess, plan, and manage people's care in collaboration with all relevant teams, including how they assess safety and risks of harm.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the effectiveness of the NHS Health Check programme in identifying chronic kidney disease; and what steps they are taking to increase uptake of that programme.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Blood pressure is a risk factor for chronic kidney disease (CKD) and cardiovascular disease (CVD). Each year, the NHS Health Check, which is a core component of England’s CVD prevention programme, engages over 1.4 million people and identifies over 340,000 cases of high blood pressure.
Individuals who are identified with high blood pressure during their NHS Health Check are referred to their general practice for further clinical investigation who determine whether an individual should be tested for CKD. Data is currently not collected on the number of individuals who are subsequently tested for CKD.
To improve access and engagement with the NHS Health Check, we are developing the NHS Health Check Online service that people can use at home, at a time convenient to them, to understand and act on their CVD risk. The NHS Health Check Online is being piloted in multiple local authorities across England.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 19 January (HL13473), whether the department has considered allowing the term probiotic to be used in mandatory product labelling, notwithstanding its current treatment as a health claim.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The information that must be provided and can be provided on food labels is set out in legislation. The use of specific terms and statements that can be made on food labels is also subject to nutrition and health claims legislation. ‘Probiotic’ is a term commonly used to describe the effect of one or more strains of live bacteria used in food and food supplements. The Department considers the term ‘probiotic’ to constitute a health claim, as it implies that consuming a food or food supplement containing these bacteria may provide a health benefit. The term ‘probiotic’ could only be used on food labels if a specific authorised health claim existed for the particular strain of live bacteria used, which have been scientifically substantiated and authorised in accordance with nutrition and health claims legislation.
There are currently no authorised health claims for probiotics or specific bacterial strains.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department for Science, Innovation & Technology:
To ask His Majesty's Government how many active users the GOV.UK App has, as of the most recent date for which data exists; what targets they have set for user growth in 2026-27; and what assessment they have made of the digital skills support required to increase uptake among digitally excluded groups.
Answered by Baroness Lloyd of Effra - Baroness in Waiting (HM Household) (Whip)
As of 16 March 2026, the GOV.UK App has an estimated total of over 230,000 active users. Analytics tracking captures only those who opt in, so this figure is higher than the number of users providing consent. To date, approximately 135,000 users have consented to analytics tracking, averaging around 23,000 consented users per month.
While the Government has not set formal numerical targets for 2026–27, the strategic aim is to drive sustained growth by making the GOV.UK App the most convenient and trusted way for people to access government services. Growth is expected as new features and services are introduced, alongside improvements in personalisation and ongoing focus on user needs, in line with the Government Digital Service’s roadmap for modern digital government.
The Government is also committed to addressing digital exclusion. The GOV.UK App has been designed to be simple and accessible, informed by user research conducted during its public beta and in line with GOV.UK accessibility standards. Alongside this, the Government will continue to assess the digital skills support needed, including understanding barriers faced by digitally excluded groups and working with departments, local authorities and delivery partners to provide assisted digital support and signposting to digital skills training. Services will continue to be available through multiple channels, ensuring that those who are unable to use digital services can still access government support.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they are taking at the national level to ensure that International Classifications of Diseases for Mortality and Morbidity Statistics-11 coding practices in the NHS capture the role of psychiatric illness in cases of organ failure or suicide.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Office for National Statistics (ONS) is responsible for coding causes of death using the International Classification of Diseases, Tenth Revision (ICD‑10). This is separate from hospital morbidity coding undertaken within the National Health Service. The response below therefore relates to morbidity coding and applies to cases of attempted suicide and organ failure for patients admitted to hospital alive.
ICD-11 is the International Classification of Diseases for Mortality and Morbidity Statistics, Eleventh Revision, and is not yet approved as an Information Standard under section 250 of the Health and Social Care Act, and so ICD‑10 remains the mandated classification for NHS morbidity data.
Under current national coding guidance, all conditions identified in the medical record by the responsible consultant as relevant to the episode of care are coded. Where a clinical link has been established between a psychiatric condition and outcomes such as organ failure or an episode of attempted suicide, each of these conditions is coded in line with this guidance.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what recent guidance they have issued to medical practitioners about the requirement to record eating disorders as a contributory or underlying cause on medical certificates of cause of death.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Medical Examiner produces the Good Practice Series, a topical collection of focused summary documents, designed to be easily read and digested by busy front-line staff, including medical practitioners, with links to further reading, guidance, and support. The collection is published online by the Royal College of Pathologists.
In June 2022, the National Medical Examiner’s Good Practice Series No. 7 - Mental health and eating disorders was published, and a copy is attached. The paper explores the role medical examiners can play in identifying links between mental health disorders and causes of death, notifying others when lessons can be learned so that care of future patients with mental health conditions is improved, and ensuring medical certificates of cause of death are completed appropriately.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they have considered the development of a national testing "cancer manual" to support the consistent delivery, governance and expansion of genomic and non-genomic biomarker testing within routine cancer pathways.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Cancer Plan for England sets out the Government’s commitment to expand and integrate biomarker testing, including blood-based biomarkers known as liquid biopsies and genomic testing, across cancer services to improve treatment selection and outcomes. In particular, the plan commits that every cancer patient who needs a genomic test to guide their treatment will receive one, with the results returned in time to inform clinical decisions. To achieve this, the National Health Service is integrating testing across pathology networks and the Genomic Medicine Service, ensuring that multidisciplinary teams (MDTs) have timely access to test results when determining the best treatment options. Ongoing investments in diagnostic infrastructure, for example, in digital pathology and comprehensive molecular profiling of cancers, will support this integration and enable earlier use of precision medicines in routine pathways. This joined-up approach means that genomic and other biomarker test results will directly inform MDT decision-making and help clinicians match patients to the most effective therapies.
The NHS Genomic Laboratory Hubs deliver testing as directed by the National Genomic Test Directory (the Test Directory), which includes tests for over 7,000 rare diseases and over 200 cancer clinical indications, including both whole genome sequencing (WGS) and non-WGS testing. The Test Directory outlines the nationally commissioned genomic testing offer, including the eligibility for testing, the test method, and target genes. NHS England, supported by a Genomics Clinical Reference Group and expert Test Evaluation Working Groups, reviews the Test Directory to keep pace with scientific and technological advances, while delivering value for money for the NHS. A robust and evidence based process and policy is in place to routinely review the Test Directory and ensure that genomic testing continues to be available for all patients for whom it would be of clinical benefit.
The National Cancer Plan also confirms that over the next five years, the NHS Genomic Medicine Service will extend ctDNA and other biomarker testing to other cancers beyond lung, colorectal, and breast cancer, subject to efficacy and value for money, further embedding precision diagnostics into routine care.
As part of a new approach to quality in cancer care, the National Cancer Plan introduces the development of new cancer manuals. These manuals will set out national standards for cancer care by tumour type. NHS England is working with clinical experts and stakeholders on the scope of these cancer manuals. Further details on their implementation, including specific guidance on diagnostics and testing, will be set out in due course.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department for Science, Innovation & Technology:
To ask His Majesty's Government whether they plan to introduce a further phase of the Digital Inclusion Innovation Fund from April 2026; what budget has been allocated for any such phase; and when they will announce the outcome of any such phase.
Answered by Baroness Lloyd of Effra - Baroness in Waiting (HM Household) (Whip)
The Digital Inclusion Innovation Fund was designed as a one-year programme to understand what works in digital inclusion, and how best practice or innovative approaches can be scaled to maximise local impact across the UK.
We remain committed to building a digitally inclusive society where no one is left behind, and plans for future support for digital inclusion are still in development.